Edgewise Therapeutics, Inc. Common Stock
$43.63
-$0.99 (-2.22%)
$42.61Day Range$45.02
Key Statistics
Market Cap
$4.74B
Shares Outstanding
108.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 26, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$44.69
Day High
$45.02
Day Low
$42.61
Volume
2.97M
VWAP
$43.62
Prev Close
$44.62
Transactions
--
Acc. Volume
--
About Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
PHARMACEUTICAL PREPARATIONSSIC 2834127 employees1715 38TH ST, BOULDER, CO, 80301720-262-7002IPO Mar 26, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001710072
- Composite FIGI
- BBG00K4Y2H24
- Share Class FIGI
- BBG00K4Y2H33
- Ticker Root
- EWTX
- SIC Code
- 2834
About Edgewise Therapeutics, Inc. Common Stock (EWTX) Stock
Edgewise Therapeutics, Inc. Common Stock (EWTX) closed the 2026-09-15 session at $43.63, down 2.22% versus the previous close (-0.99). The stock opened at $44.69 and traded between $42.61 and $45.02 during that session. Session trading volume was 3.0M shares. The volume-weighted average price (VWAP) is $43.62.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Edgewise Therapeutics, Inc. Common Stock has a market capitalization of $4.74 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. EWTX is listed on the XNAS exchange. The company employs approximately 127 people. Edgewise Therapeutics, Inc. Common Stock is headquartered in BOULDER, CO. The recorded listing date is 2021-03-26.
On this page you can find market EWTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.